XL-652 is primarily utilized in the field of cancer research and treatment development. It functions as a multi-targeted kinase inhibitor, which means it can interfere with various signaling pathways that are crucial for cancer cell growth and survival. This makes it a valuable compound in preclinical studies aimed at understanding and combating different types of cancers. Researchers are particularly interested in its potential to inhibit specific kinases involved in tumor progression and metastasis. By targeting these kinases, XL-652 has shown promise in reducing the proliferation of cancer cells and enhancing the efficacy of other therapeutic agents. Its application extends to both in vitro and in vivo studies, where it is tested for its ability to suppress tumor growth and improve patient outcomes in various cancer models.